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ABSTRACT
Objective: To evaluate positive predictive value (PPV)
of different disease codes and free text in identifying
acute myocardial infarction (AMI) from electronic
healthcare records (EHRs).
Design: Validation study of cases of AMI identified from
general practitioner records and hospital discharge
diagnoses using free text and codes from the International
Classification of Primary Care (ICPC), International
Classification of Diseases 9th revision-clinical
modification (ICD9-CM) and ICD-10th revision (ICD-10).
Setting: Population-based databases comprising
routinely collected data from primary care in Italy and the
Netherlands and from secondary care in Denmark from
1996 to 2009.
Participants: A total of 4 034 232 individuals with
22 428 883 person-years of follow-up contributed to the
data, from which 42 774 potential AMI cases were
identified. A random sample of 800 cases was
subsequently obtained for validation.
Main outcome measures: PPVs were calculated
overall and for each code/free text. ‘Best-case scenario’
and ‘worst-case scenario’ PPVs were calculated, the latter
taking into account non-retrievable/non-assessable cases.
We further assessed the effects of AMI misclassification
on estimates of risk during drug exposure.
Results: Records of 748 cases (93.5% of sample) were
retrieved. ICD-10 codes had a ‘best-case scenario’ PPV of
100% while ICD9-CM codes had a PPV of 96.6% (95%
CI 93.2% to 99.9%). ICPC codes had a ‘best-case
scenario’ PPV of 75% (95% CI 67.4% to 82.6%) and free
text had PPV ranging from 20% to 60%. Corresponding
PPVs in the ‘worst-case scenario’ all decreased. Use of
codes with lower PPV generally resulted in small changes
in AMI risk during drug exposure, but codes with higher
PPV resulted in attenuation of risk for positive
associations.
Conclusions: ICD9-CM and ICD-10 codes have good
PPV in identifying AMI from EHRs; strategies are
necessary to further optimise utility of ICPC codes and
ARTICLE SUMMARY
Article focus
▪ This article evaluates the positive predictive value
(PPV) of different disease codes and free-text
search in identifying cases of acute myocardial
infarction (AMI) from population-based health-
care databases in three countries in Europe.
Key messages
▪ The overall PPV of different disease coding systems
for identifying AMI was good, ranging from a ‘best-
case scenario’ PPV of 75% (International
Classification for Primary Care (ICPC), Netherlands)
to 95% (International Classification of Diseases 9th
revision-Clinical Modification (ICD9-CM)) to 100%
(ICD-10th revision (ICD-10), Denmark). These find-
ings are consistent with PPV estimates for
ICD9-CM and ICD-10 cited in the literature. Until
now, there is no study describing the PPV of ICPC
codes for identifying AMI.
▪ Use of free text alone had a lower PPV, ranging
from ‘best-case scenario’ PPV of 20–60%.
Strategies are necessary to optimise use of natural
language processing in the identification of AMI in
these electronic healthcare record (EHR) data.
▪ Misclassification of AMI cases resulting from the
use of disease codes (or free text) with low PPV
has corresponding implications in the estimation
of incidence rates. Studies using EHR data to
derive incidence rates of clinical events should
thus correct for this potential misclassification.
▪ Use of more specific disease codes for identify-
ing AMI during drug use may lead to a small but
significant change in risk estimates and at the
expense of decreased precision. Further studies
are warranted to investigate the effect of different
PPVs on outcome misclassification and should
take into account the type of database as well as
test more drug-event associations and control
for other confounders.
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free-text search. Use of specific AMI disease codes in estimation of risk
during drug exposure may lead to small but significant changes and at
the expense of decreased precision.
INTRODUCTION
Cardiovascular diseases remain an important cause of
morbidity and mortality worldwide and the conduct of
disease surveillance has changed with the availability
of secondary data sources as well as changes in disease
coding terminologies. Information derived from multi-
country databases containing electronic healthcare
records (EHRs) is increasingly being used for drug safety
surveillance, including drug-related adverse cardiovascu-
lar outcomes.1–3 Cases of acute myocardial infarction
(AMI) may be identified using electronic databases from
different countries, which may differ not only in their
healthcare systems, but also in their disease registration
and coding procedures. Innovations in recent years have
brought about discovery and subsequent clinical use of
biomarkers that allow earlier recognition of disease as
well as therapeutic interventions that reduce the extent
of myocardial injury and mortality. Such developments
have led to revisions in the definition of AMI and
changes in diagnosis and prognosis.4–6 Studies that esti-
mate AMI incidence from EHR data must also then con-
sider the implications of new diagnostic criteria on the
disease coding practices of such databases.7–10
The accuracy of specific disease coding terminologies
in identifying AMI from healthcare data has been evalu-
ated in previous studies. These studies, mostly per-
formed on data representing administrative/insurance
claims, have derived positive predictive values (PPVs) of
International Classification of Diseases-9th revision-
Clinical Modifications (ICD9-CM) codes as well as
diagnosis-related groups codes, used in billing.11–14
A recent study evaluated the PPV of ICD-10th revision
(ICD-10) diagnostic codes used to assess Charlson
comorbidity index conditions, including myocardial
infarction, in the population-based Danish National
Registry of Patients.15 Until now, there is no study that
has evaluated the validity of International Classification
of Primary Care (ICPC) codes and unstructured (free
text) search, or the combination of diagnosis codes and
free-text search, in the identification of AMI from elec-
tronic healthcare data. Furthermore, the opportunity to
simultaneously evaluate different disease coding systems
as well as free-text permits investigation of the effect of
outcome misclassification.
We conducted a validation study within the context of
the EU-ADR Project (Exploring and Understanding
Adverse Drug Reactions by Integrative Mining of
Clinical Records and Biomedical Knowledge, http://
www.euadr-project.org/). Funded by the European
Commission under its Seventh Framework Programme,
the EU-ADR Project has designed and developed a com-
puterised integrative system that exploits EHR data from
different countries (as well as biomedical data) to facili-
tate early detection of adverse drug reactions.3
Databases contributing EHR data to the Project are part
of the EU-ADR network and represent a huge resource
for monitoring of drug safety in Europe. In this valid-
ation study, we evaluated and compared PPV of free-text
search and disease codes from three different terminolo-
gies: ICPC; ICD9-CM and ICD-10 in identifying cases of
AMI from population-based healthcare databases in
Denmark, Italy and the Netherlands. We further assessed
the effect of outcome misclassification on the estimation
of risk of AMI during drug use.
METHODS
Data sources
The EU-ADR database network currently comprises
anonymised demographic and clinical data of over 20
million individuals from eight population-based EHR
databases in three European countries.3 The data are
pooled using a distributed network approach that allows
data holders to maintain control over their protected
data. Validation of AMI case identification was per-
formed in three of these databases: (1) Integrated
Primary Care Information (IPCI, the Netherlands);
(2) Health Search/CSD Patient DB (HSD, Italy) and
(3) Aarhus University Hospital Database (Aarhus,
Denmark). IPCI and HSD are both general practice
(GP) databases documenting patient consults, including
referrals for hospitalisation or specialist care as well as
prescriptions for medications. Aarhus is a comprehen-
sive record-linkage database system in which drug dis-
pensation data are linked to a registry of hospital
discharge diagnoses and various other registries, includ-
ing death registries. All these databases have been exten-
sively used for epidemiological research.16–18 A more
detailed description of the characteristics of the data-
bases has been previously published.3 19 A table of
ARTICLE SUMMARY
Strengths and limitations of this study
▪ Large healthcare databases covering a total population of over
four million from three countries were investigated— a formid-
able challenge in itself because of the diversity in healthcare
and disease coding practices. The implementation of a stan-
dardised validation questionnaire facilitated harmonised data
collection and analysis across databases without compromis-
ing data protection. The opportunity to simultaneously evaluate
different disease coding systems as well as free text also
allowed the investigation of the effect of outcome
misclassification.
▪ This study evaluated the accuracy of the codes using the PPV;
however, there are other measures such as sensitivity and
negative predictive value that could not be calculated.
▪ Despite the reasonable size of the random sample used in this
validation study, it was not adequate to permit evaluation of
some of the individual, less frequently occurring, codes.
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database characteristics of the entire EU-ADR network is
provided in online supplementary appendix 1. The
three databases employ different disease coding termin-
ologies: IPCI uses ICPC; HSD uses ICD9-CM and Aarhus
uses ICD-10. Clinical narratives from general practi-
tioners’ notes in both HSD and IPCI are also recorded
as unstructured text that can be used to identify medical
events. Standardised data extraction was carried out
using the Java-based software Jerboa, developed within
the EU-ADR Project.3
Cohort definition and follow-up time
To harmonise follow-up definitions across databases, we
defined the eligibility period for each patient as starting
on the date of registration in the database and ending
on the date the patient transfers out of the system, with
the last supply of data, occurrence of AMI (as described
below) or on the patient’s death, whichever is earlier. In
order to be included in the study cohort, participants
had to have at least 1 year of continuous and valid data.
Identification of AMI
Potential cases of AMI were initially identified using har-
monised and database-specific codes derived from hos-
pital discharge diagnoses (in the case of Aarhus) or
from general practitioner diagnoses (in the case of IPCI
and HSD). These codes included the ICPC code K75
(IPCI), ICD9-CM codes 410/410.x/410.x0 (HSD), and
the ICD-10 codes I21.x (Aarhus). IPCI and HSD also
performed free-text search using specific key words. The
ICD9-CM code 411.81 (corresponding to acute coronary
occlusion) was specifically used in HSD, in combination
with free text to refine the search. The free-text search
strings employed in IPCI and HSD are given in online
supplementary appendix 2. The process of mapping and
harmonisation of event data extraction from different
EHR databases in the EU-ADR project was based on
medical concepts derived from the Unified Medical
Language System.20 21 We only considered the first
occurrence (first diagnosis) of AMI in each patient.
Case validation
Random sampling of cases for validation was carried out
separately in each of the three databases using a specific
module in the Jerboa software designed for this
purpose. The module uses the standard random func-
tion in Java that generates random numbers. We
required a sample size of 200 cases/database. Since the
use of free-text search was known to be more extensive
in IPCI, an additional 200 potential cases identified by
free text were obtained in IPCI. A manual review of GP
records and hospitalisation charts was performed by
medically trained assessors using a standardised ques-
tionnaire, pilot-tested in the databases and reviewed by a
panel of experts. Diagnostic criteria for AMI as pre-
scribed in the current guidelines4 7 were incorporated in
the questionnaire, as well as information regarding car-
diovascular risk factors and potential alternative
diagnoses that could explain findings suggestive of AMI.
For GP databases (IPCI and HSD), it was also deter-
mined whether the AMI diagnosis was made either dir-
ectly by the general practitioner or by a medical
specialist. The standardised questionnaire was then
implemented as a computerised data entry algorithm
using the custom-built software Chameleon. This soft-
ware was installed locally in each database, allowing the
data holders to keep patient-level data within their pro-
tected environment. The data entry algorithm is shown
in figure 1 and the questionnaire in online supplemen-
tary appendix 3. On the basis of the information col-
lected in the questionnaire, the potential AMI cases
were classified as: (1) definite case; (2) non-case or
(3) non-assessable case, if the available information was
deemed to be insufficient for the case validation.
Assessment of index date
We determined how the coded date of the event (which
is detected automatically) was related to the actual date
of diagnosis of AMI and to the date of onset of first
symptoms, as derived from manual validation. In add-
ition, for the administrative database Aarhus, we com-
pared the coded date with the date of hospital
admission related to the pertinent case.
Statistical analyses
A. PPV and corresponding 95% CI were calculated
overall in each database and specifically for each
code or free-text search, using medical charts as the
gold standard. PPV was calculated as the proportion
of the number of confirmed AMI cases out of the
total number of randomly selected potential cases.
Non-assessable cases were not initially included in
either the numerator or the denominator for the
PPV calculation, under the assumption that these
would not constitute significant bias. However,
because the number of non-assessable and non-
retrievable cases turned out to be unexpectedly high,
we defined, a posteriori, two levels of PPV in order to
account for the effects of both non-retrievable and
non-assessable cases. We recalculated a ‘worst-case
scenario’ PPV as the proportion of confirmed AMI
cases out of the total number of randomly selected
potential cases, this time including both non-
retrievable and non-assessable cases. We retained as a
‘best-case scenario’ PPV the proportion of confirmed
AMI cases out of the total number of cases that
excluded both non-retrievable and non-assessable
cases.
B. Effect of outcome misclassification on AMI risk estimation
during drug use. To investigate the impact of outcome
misclassification on estimation of risk of drug-related
AMI, we evaluated the association between drug
exposure and risk of AMI in the entire population
covered by the three databases (ie, not only the ran-
domly selected cases). Drug prescription and/or
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dispensation data were used to estimate the inci-
dence rate of AMI during drug exposure. Drug pre-
scriptions and dispensations are locally coded in
each database (see online supplementary appendix
1), but these codes are linked to the Anatomical
Therapeutic Chemical Classification (ATC, http://
www.whocc.no/atc_ddd_index/) system, which is
used as the common drug coding system in the
EU-ADR network. Overlapping treatment episodes
with the same drug (same ATC code) are combined
into a single episode of drug use that starts when the
first prescription begins and stops when the last pre-
scription ends. When a patient uses more than one
drug at a time, the corresponding person-time is
labelled accordingly. Using individual data on the
start date and end date of prescription or dispensa-
tion, those periods during which an individual is
included in the study, but is not using any drug, are
marked as unexposed. Events are then assigned to
the episodes (ie, drug use/non-use) in which they
occurred. The duration covered by each prescription
or dispensation is estimated within each database,
according to the legend duration (if dosing regimen
is available), or is otherwise based on the defined
daily dose. We estimated the incidence rate of AMI
during the current use of six reference drugs: three
drugs well known from the literature to be positively
associated with AMI (positive controls: rofecoxib,
rosiglitazone and levonorgestrel/oestrogen); and
three other drugs, unlikely to be associated with
AMI, based on the currently available literature
(negative controls: ferrous sulfate, gemfibrozil,
amoxicillin/clavulanic acid).22 We employed the case
definitions of AMI taking into account codes and
free text with varying values of PPV: (1) ‘AMI’
included all eligible codes and free text to identify
patients with AMI; (2) ‘AMI50’ included codes and
free text having PPV ≥50% and (3) ‘AMI75’ included
codes and free text having PPV of ≥75%. We calcu-
lated incidence rate ratios (IRRs) for AMI during
drug exposure (with non-exposure to the specified
drug as reference) for each of the six drugs, pooled
across all the databases. A Mantel-Haenszel test was
used to assess the differences between the incidence
rates, corrected for age and sex.
RESULTS
The three healthcare databases considered for this ana-
lysis comprised data from 4 034 232 individuals with
22 428 883 person-years of follow-up during the period
1996–2009. Within this population, a total of 42 774
potential cases of AMI were identified. From the
random sample of 800 potential cases of AMI (200
Figure 1 Data entry algorithm implemented based on a standardised questionnaire.
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cases/database plus an additional 200 cases for free
text-identified cases in IPCI) selected for validation, the
medical records/charts could be retrieved and reviewed
for 748 (93.5%) of them. The hospital medical charts of
52 potential cases in Aarhus could not be accessed
because no institutional agreement was in place to allow
access to the medical charts. The demographic and clin-
ical characteristics of the randomly selected 748 cases
are shown in table 1. The mean age was 67 years across
all the databases and the patients were predominantly
men (62–70% overall). Chest pain at rest or with exer-
tion was the most frequently reported symptom of AMI
cases across all the databases (more than 50% of con-
firmed cases in both IPCI and Aarhus and 11% in
HSD). Hypertension, cigarette smoking and dyslipidae-
mia were the most frequently recorded cardiovascular
risk factors.
All 148 potential cases of AMI identified in Aarhus
were confirmed by manual chart review. As regards IPCI,
93 (46.5%) potential ICPC-coded cases were confirmed,
31 (15.5%) were judged as non-cases and 76 (38%)
cases were judged as non-assessable. From the 200
potential cases identified by free-text search, 26 (13%)
cases were confirmed and 68 (34%) were considered
non-assessable, while the remaining (106, 53%) were
classified as non-cases. For HSD, 115 (57.5%) cases were
confirmed and 79 (39.5%) were declared non-assessable.
Table 2 shows the ‘best-case scenario’ PPV and ‘worst-
case scenario’ PPV overall for the codes used to identify
AMI in each database. In table 3, the percentage distri-
bution and PPV for the specific diagnosis codes from
each coding scheme and free-text search are given. All
the ICD-10 codes used in Aarhus had the 100% ‘best-
case scenario’ PPV. The PPVs in the ‘worst-case scenario’
all decreased, ranging from 66.7 (95% CI 1.3 to 100) to
75.0 (95% CI 58.7 to 91.3). Overall, the ICD9-CM codes
had good PPV, with 410.9*, the most frequently reported
code, having a ‘best-case scenario’ PPV of 96.9% (95%
CI 93.5% to 100%) and a ‘worst-case scenario’ PPV of
59.9 (95% CI 50.1 to 69.6). The ‘best-case scenario’ PPV
of free-text search alone in HSD was 60% (95% CI 17.1
to 100). In IPCI, the ICPC code K75 had a ‘best-case
scenario’ PPV of 75% (95% CI 67.4% to 82.6%), while
free-text search alone had a PPV of 19.7% (95% CI
12.9% to 26.5%). The ‘worst-case scenario’ PPVs were
correspondingly lower. All validated cases of AMI in IPCI
and HSD were supported with confirmation of the diag-
nosis by a medical specialist (ie, cardiologist).
The relationship between the coded date and the date
of onset of symptoms across the three databases is shown
in figure 2. There was not enough information for this
assessment in 25 cases from Aarhus (16.9%). The lag
time between coded date and date of symptom onset (as
manually validated) ranged from 1 day before to more
than 60 days before the automatically detected event
date. The coded date for the majority of cases coincided
with the onset of symptoms in all databases: Aarhus=72
cases (48.6%); HSD=110 cases (95.6%) and IPCI=67
cases (56.3%). For the administrative/claims database
Aarhus, the characterisation of the coded index date
with respect to hospitalisation is as follows: (1) date of
hospital admission=100 cases (67.6%); (2) during hos-
pital stay=9 cases (6.1%); (3) ≥7 days preceding hospital-
isation 23 (15.5%) and (4) not possible to establish=16
(10.8%).
Figure 3 shows the IRRs, adjusted for age and sex, for
six drugs across the different PPV categories. In general,
although the number of AMI cases identified using all
eligible codes (‘AMI’) was greater compared with case
definitions based on code with ≥50% PPV or ≥75% PPV
(ie, ‘AMI50’ and ‘AMI75’), there was only a small
change in the resulting IRRs. The clear exception is the
positive control drug rosiglitazone, in which the IRR of
2.44 (95% CI 1.62 to 3.67) with the ‘AMI definition’
decreased to 1.62 (95% CI 0.77 to 3.41) with ‘AMI75,’
the risk then becoming insignificant; the IRR remained
fairly stable at 1.64 (95% CI 0.78 to 3.45) with the
‘AMI50’ definition. The same trend was observed for
rofecoxib and levonorgestrel/oestrogen: although the
IRR changes corresponding to each definition were
smaller compared with rosiglitazone, the risk disap-
peared with both the ‘AMI75’ and ‘AMI50’ definitions.
For the negative controls (where the 95% CIs all
included 1), the impact of using codes with different
PPVs was less pronounced.
DISCUSSION
We examined PPV of primary hospital discharge diagno-
sis codes and general practitioner-recorded diagnoses
for AMI in three European EHR databases. The overall
‘best-case scenario’ PPV for the coding scheme-based
diagnoses was good, ranging from 75% (IPCI, ICPC
coding) to 95% (HSD, ICD9-CM) to 100% (Aarhus,
ICD-10). The use of free-text search was more extensive
in IPCI compared with HSD, largely due to the lesser
granularity of the ICPC coding system. The use of free
text alone had a lower PPV, ranging from a ‘best-case
scenario’ PPV of 20% in IPCI to 60% in HSD. Although
52 of the initially identified cases of AMI in Aarhus were
missing and could not be validated, the inaccessibility of
the corresponding medical charts was random and thus
was deemed unlikely to introduce bias. However, to
account for any potential bias introduced by these non-
retrievable cases (as well as non-assessable cases), ‘worst-
case scenario’ PPVs were calculated. The impact on the
corresponding PPVs was high: for ICD-10 codes overall,
PPV dropped to 74% while for ICD9-CM and ICPC
codes PPV decreased to 60% and 46%, respectively.
These findings reiterate the need for adequate case
retrieval in outcome validation studies and, if necessary,
to perform resampling and take into account the impact
of missing cases in the analysis. More importantly, mis-
classification of AMI cases resulting from use of disease
codes (or free text) with low PPV has analogous implica-
tions on the estimation of incidence rates. Studies using
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Table 1 Characteristics of patients in the random sample of potential AMI cases
IPCI HSD Aarhus
Total N: 400 (%)
Confirmed cases
N: 93 (%) Total N: 200 (%)
Confirmed
cases N: 115 (%)
Total N:
148 (%)
Confirmed
cases N: 148 (%)
Male sex (%) 246 (61.5) 87 (93.5) 132 (66.0) 80 (69.6) 103 (69.6) 82 (55.4)
Mean age (years) 66 65 68 67 67 67
Cardiovascular risk factors*
Family history of coronary heart disease 86 (21.5) 14 (15.1) 11 (5.5) 8 (7.0) 19 (12.8) 19 (12.8)
Dyslipidaemia 73 (18.2) 19 (20.4) 98 (49.0) 58 (50.4) 19 (12.8) 19 (12.8)
Diabetes mellitus 62 (15.5) 13 (14.0) 66 (33.0) 42 (36.5) 17 (11.4) 17 (11.4)
Hypertension 126 (31.5) 36 (38.7) 113 (56.5) 76 (66.0) 44 (29.7) 44 (29.7)
Obesity 79 (19.8) 23 (24.7) 21 (10.5) 16 (13.9) 7 (4.7) 7 (4.7)
Cigarette smoking 111 (27.8) 36 (38.7) 39 (19.5) 22 (19.1) 50 (33.8) 50 (33.8)
Clinical manifestations*
Chest, jaw or upper extremity pain at rest or with exertion 102 (25.5) 52 (55.9) 23 (11.5) 13 (11.3) 118 (79.7) 118 (79.7)
Difficulty breathing (dyspnoea) 38 (9.5) 15 (20.4) 10 (5.0) 6 (5.2) 22 (14.8) 22 (14.8)
Excessive sweating (diaphoresis) 30 (7.5) 19 (20.4) 2 (1.0) 0 (0) 5 (3.4) 5 (3.4)
Fatigue/weakness 7 (1.8) 0 (0) 2 (1.0) 1 (0.9) 5 (3.4) 5 (3.4)
Diagnostic workup performed*
Coronary angiography 48 (12.0) 39 (41.9) 39 (19.5) 38 (33.0) 117 (79.1) 117 (79.1)
ECG
ST-segment elevation 27 (6.7) 25 (30.1) 7 (3.5) 5 (4.4) 59 (39.9) 59 (39.9)
New Q waves 7 (1.8) 4 (4.3) 1 (0.50) 1 (0.9) 9 (6.1) 9 (6.1)
New left bundle branch block (LBBB) 3 (0.8) 0 (0) 0 (0) 0 (0) 2 (1.4) 2 (1.4)
T wave inversion 17 (4.2) 9 (9.7) 8 (4.0) 6 (5.2) 19 (12.8) 19 (12.8)
Other (ST segment depression, etc) 19 (7.2) 19 (20.4) 7 (3.5) 7 (6.1) 9 (6.1) 9 (6.1)
Cardiac enzymes
Elevated cardiac troponin I 5 (1.2) 41 (44.1) 2 (1.0) 2 (1.7) 0 (0) 0 (0)
Elevated cardiac troponin T 6 (1.5) 6 (9.7) 0 (0) 0 (0) 123 (83.1) 123 (83.1)
Elevated creatine phosphokinase (MB isoenzyme) 23 (5.8) 23 (24.7) 5 (2.5) 5 (4.4) 86 (58.1) 86 (58.1)
Other 8 (2.0) 5 (5.4) 3 (1.5) 3 (2.6) 5 (3.4) 5 (3.4)
Interventions performed*
Coronary artery bypass graft (CABG) 15 (3.8) 10 (10.8) 17 (8.5) 17 (14.8) 7 (4.7) 7 (4.7)
Percutaneous coronary intervention (PCI) 78 (19.5) 67 (72.0) 41 (20.5) 41 (35.6) 93 (62.8) 93 (62.8)
Thrombolysis (rTPA/streptokinase, others) 6 (1.5) 5 (5.4) 4 (2.0) 4 (3.5) 9 (6.1) 9 (6.1)
Initiation of long-term pharmacotherapy 116 (29.0) 93 (100) 121 (60.5) 90 (77.6) 81 (56.8) 81 (56.8)
Deaths with AMI identified as cause 7 (1.8) 7 (7.5) 2 (1.0) 2 (1.7) 2 (1.4) 2 (1.4)
Diagnosis confirmed by medical specialist† 113 (28.2) 93 (100) 1 (0.5) 1 (0.9) NA NA
*Can add up to more than 100%.
†Only applicable for GP databases (HSD and IPCI).
AMI, acute myocardial infarction; HSD, Health Search/CSD Patient DB; IPCI, Integrated Primary Care Information.
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EHR data to derive incidence rates of clinical events
should thus correct for this potential misclassification.
Routinely collected EHR data are increasingly being
used in many areas of biomedical research and a
recently identified promising area for EHRs is the pro-
active surveillance of potentially drug-induced outcomes.
The validity of such surveillance activities depends,
however, on the accuracy of the definitions of the out-
comes being investigated, while at the same time pre-
serving data confidentiality. The use of a standardised
questionnaire implemented in an automated data entry
validation algorithm facilitated harmonised data collec-
tion and analysis across different databases without com-
promising data protection. The procedure also enabled
us to document recorded database information on car-
diovascular risk factors such as a family history of coron-
ary artery disease, hypertension, diabetes, dyslipidaemia,
smoking and obesity. Such information may be useful in
evaluating potential confounder effects when conduct-
ing epidemiological studies. Other information related
to diagnostic procedures or interventions requiring hos-
pitalisation (eg, coronary angiography) may not be con-
sistently recorded in GP databases, unless provided with
the discharge letters or referrals from specialists, hence
the observed higher proportion of such information
from reimbursement claims data (Aarhus). In the same
way, the documentation of initiation of long-term
pharmacotherapy for the management of AMI may not
be as well documented in claims data as in GP data. It is
important to note that information derived from GP
databases are data recorded in the course of routine
clinical care and provide a different perspective from
those derived from databases documenting reimburse-
ment claims for utilisation of healthcare services, which
are more for auditing purposes.23 24
Since the context within which clinical events are
recorded differs between GP databases and administra-
tive/claims databases, there is often also an expected
delay between onset of first symptoms (which are more
likely to be documented in GP records) and diagnoses
recorded upon hospital discharge (documented in reim-
bursement claims, and also in GP data if referral letters
from a cardiologist are available). Our evaluation of the
automatically detected index date shows that most of the
time the coded event date coincided with the date of
onset of first symptoms (and with the date of hospital
admission for the administrative database), although
there can be a wide range between these two dates.
For this validation study, we have chosen PPV as the
relevant measure of accuracy for the codes used in iden-
tifying AMI from EHR. Such a metric enables the use of
GP and claims records to determine the probability that
an individual has an AMI, based on such data. PPV mea-
surements are correlated with disease prevalence,
however, and are strongly dependent on specificity.
Specificity and other measures of validity, such as sensi-
tivity (ie, how many cases of AMI are missed) and nega-
tive predictive value, cannot be calculated from our
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Table 3 Number and distribution of confirmed AMI cases by diagnostic code or free text
Database/code Code description
Number of
records
reviewed
Number of
cases
confirmed
Percentage of cases
identified by such code
or free text in random sample
PPV, best-case
scenario† (95% CI)
PPV, worst case
scenario‡ (95% CI)
IPCI
ICPC K75- AMI 200 93 100 75.0 (67.4 to 82.6) 46.5 (37.7 to 55.3)
Free text Specific key words* 200 26 100 19.7 (12.9 to 26.5) 13.0 (7.3 to 18.7)
HSD
ICD9-CM
410 or 410.0 AMI of anterolateral
wall
12 6 6.0 85.7 (59.8 to 100) 50.0 (13.0 to 87.0)
410.1 or 410.10 AMI of other anterior
wall
4 4 2.0 100 100
410.20 AMI of inferolateral wall 1 1 0.5 100 100
410.3 AMI of inferoposterior
wall
1 1 0.5 100 100
410.7 Subendocardial
infarction
3 2 1.5 100 66.7 (1.3 to 100)
410.9 or 410.90 AMI, unspecified site 157 94 78.5 96.9 (93.5 to 100) 59.9 (50.1 to 69.6)
410.9+Free text AMI, unspecified site 8 4 4.0 100 50.0 (1.0 to 99.0)
411.81+Free
text
Acute coronary
occlusion without MI
1 0 0.5 0 0
Free text Specific key words* 13 3 6.5 60 (17.1 to 100) 23.1 (0 to 60.0)
Aarhus
ICD-10
I21.0 Acute transmural MI of
anterior wall
20 20 13.5 100 74.1 (54.9 to 93.3)
I21.1 Acute transmural MI of
inferior wall
17 17 11.5 100 73.9 (53.0 to 94.8)
I21.2 Acute transmural MI of
other sites
2 2 1.4 100 66.7 (1.3 to 100)
I21.3 Acute transmural MI of
unspecified site
26 26 17.6 100 74.3 (57.5 to 91.1)
I21.4 Acute subendocardial
MI
56 56 37.8 100 73.7 (62.2 to 85.2)
I21.9 AMI, unspecified 27 27 18.2 100 75.0 (58.7 to 91.3)
*See online supplementary appendix 2 for key words used.
†Best-case scenario: non-assessable and non-retrievable cases are not included in the numerator or denominator when the PPV is calculated.
‡ Worst-case scenario: both non-assessable and non-retrievable cases are included in the denominator when the PPV is calculated. For Aarhus, the number of cases that would have been
retrieved per code was estimated based on the % distribution of codes in the retrieved cases within the random sample.
AMI, acute myocardial infarction; HSD, Health Search/CSD Patient DB; ICD9-CM, International Classification of Diseases 9th revision-clinical modification; ICPC, International Classification of
Primary Care; IPCI, Integrated Primary Care Information.
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data, because the data extraction was based on searching
for the codes/free text pertinent to the diagnosis of
interest. Another limitation is that, in the estimation of
drug-related IRR of AMI, we only adjusted for age and
sex and did not consider other potential confounding
factors.
The results we obtained in this study are consistent
with the PPV estimates for ICD-10 and for ICD9-CM
cited in the literature. The ICD-10 codes I21, I22 and
I23 were found to have 98% PPV in a Danish study
evaluating the accuracy of ICD-10-coded myocardial
infarction as a component of the Charlson comorbidity
index.15 Previous studies evaluating earlier versions of
ICD have also demonstrated the accurate coding prac-
tices in Danish administrative registries, including the
Danish MONICA (Monitoring Trends and Determinants
in Cardiovascular Disease) study where 93.5% of the
patients in the Danish National Patient Register were
found to have definite or possible AMI.25 The PPV of
the ICD9-CM code 410 to identify cases of AMI among
records with a prior primary hospital discharge code in
the Saskatchewan Hospital Automated Database was
97%.12 In another study using Medicare claims, the PPV
of several ICD9-CM codes (410.01, 410.11, 410.21,
410.31, 410.41, 410.51, 410.61, 410.71, 410.81 or 410.91)
for identifying AMI in either primary or secondary hos-
pital discharge diagnoses was 94.1%.11 While ICPC
codes are often used to estimate the incidence or preva-
lence of various clinical outcomes,26–28 we are not aware
of any published studies that have assessed the accuracy
of ICPC codes in the identification of AMI in EHR data.
A study in the Netherlands evaluated ICPC-coded diag-
noses in GP records in the context of cardiovascular risk
factor assessment after pre-eclampsia, but only the valid-
ity of an ICPC-coded pre-eclampsia diagnosis was
determined.29
The available knowledge regarding the value of free-
text mining in identifying outcomes from EHR data is
an area of research that is gaining a lot of interest.30 31
Our findings show that there is potential for the use of
free-text search in identification of AMI from EHR data-
bases, but that appropriate combination of key words
and natural language processing techniques needs to be
further evaluated and optimised.
Our investigation of the impact of outcome misclassifi-
cation on estimation of AMI risk with drug use showed
that the use of codes with lower PPV generally resulted
in small changes in the estimated relative risks, but the
use of codes with higher PPV may lead to attenuation or
disappearance of risk for positive associations (non-
differential misclassification biases the risk estimates
towards the null). It is important to note that the
change in the estimated risk of AMI during drug use
when using more specific criteria is virtually due to the
exclusion of AMI cases identified by free-text search:
with AMI50, cases identified by free text in IPCI were
excluded while with AMI75 all cases identified by free
text in IPCI and HSD were excluded. The impact
Figure 2 Differences in
automatically recorded date of
acute myocardial infarction (AMI;
time 0) and manually validated
date of onset of AMI symptoms
across the databases.
Figure 3 Impact of codes and
free text with different ‘best-case
scenario’ positive predictive
values on age-adjusted and
sex-adjusted incidence rate ratio
estimates for acute myocardial
infarction during drug exposure
(non-exposure to the same drug
as reference).
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analyses were performed on aggregated data, but should
ideally be stratified according to database. This is
because the impact on IRR is not only a function of
using specific versus non-specific codes, but also a func-
tion of the database characteristics. Future studies
should thus take into account the data source as well as
test more drug-event associations, control for other con-
founders and increase sample size, especially since these
estimates were based on relatively small numbers (as
reflected in the wide CI). Although we considered only
the ‘best-case scenario’ PPVs in the analyses for outcome
misclassification, these findings suggest that similar
implications would be expected with the ‘worst-case
scenario’ PPVs.
CONCLUSIONS
We have shown that a network of EHR databases from
different countries with different disease coding systems
can accurately identify patients with AMI and that
adequate case retrieval remains an essential step in valid-
ation. The results obtained in this study are consistent
with the PPV estimates for ICD9-CM and ICD-10 cited in
the literature. Strategies are necessary to optimise the
use of ICPC, in combination with free-text search, in the
identification of AMI from EHR data. Use of more spe-
cific disease codes for identifying AMI during drug use
may lead to a small but significant change in risk esti-
mates and at the expense of decreased precision.
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